Citigroup Increases Colgate-Palmolive (NYSE:CL) Price Target to $100.00

Colgate-Palmolive (NYSE:CL) had its target price hoisted by equities research analysts at Citigroup from $95.00 to $100.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price objective indicates a potential upside of 15.25% from the stock’s previous close.

CL has been the topic of a number of other reports. JPMorgan Chase & Co. boosted their target price on Colgate-Palmolive from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, January 18th. Morgan Stanley upped their target price on Colgate-Palmolive from $85.00 to $93.00 and gave the stock an “overweight” rating in a report on Monday, January 29th. The Goldman Sachs Group initiated coverage on Colgate-Palmolive in a report on Friday, March 1st. They set a “buy” rating and a $93.00 price objective for the company. Wells Fargo & Company increased their price target on Colgate-Palmolive from $80.00 to $88.00 and gave the stock an “equal weight” rating in a research report on Monday, January 29th. Finally, TheStreet upgraded Colgate-Palmolive from a “c+” rating to a “b+” rating in a research report on Friday, January 26th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $89.50.

Colgate-Palmolive Price Performance

CL opened at $86.77 on Tuesday. The stock’s 50 day simple moving average is $86.97 and its 200 day simple moving average is $80.63. The company has a debt-to-equity ratio of 8.59, a current ratio of 1.11 and a quick ratio of 0.71. Colgate-Palmolive has a 1 year low of $67.62 and a 1 year high of $90.37. The firm has a market cap of $71.32 billion, a price-to-earnings ratio of 31.21, a PEG ratio of 3.28 and a beta of 0.42.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings data on Friday, January 26th. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.02. The firm had revenue of $4.95 billion for the quarter, compared to analyst estimates of $4.89 billion. Colgate-Palmolive had a return on equity of 509.75% and a net margin of 11.82%. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period last year, the company earned $0.77 EPS. As a group, analysts predict that Colgate-Palmolive will post 3.49 earnings per share for the current year.

Insider Buying and Selling at Colgate-Palmolive

In related news, CEO Noel R. Wallace sold 29,772 shares of Colgate-Palmolive stock in a transaction on Friday, February 16th. The shares were sold at an average price of $84.06, for a total value of $2,502,634.32. Following the completion of the sale, the chief executive officer now owns 301,343 shares of the company’s stock, valued at approximately $25,330,892.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, insider Jennifer Daniels sold 61,633 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $83.93, for a total transaction of $5,172,857.69. Following the completion of the transaction, the insider now owns 57,948 shares of the company’s stock, valued at $4,863,575.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Noel R. Wallace sold 29,772 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $84.06, for a total value of $2,502,634.32. Following the transaction, the chief executive officer now directly owns 301,343 shares of the company’s stock, valued at approximately $25,330,892.58. The disclosure for this sale can be found here. In the last 90 days, insiders sold 232,371 shares of company stock valued at $19,505,099. 0.37% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Colgate-Palmolive

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. OFI Invest Asset Management purchased a new stake in shares of Colgate-Palmolive in the third quarter worth $25,000. Union Savings Bank grew its stake in shares of Colgate-Palmolive by 76.6% in the fourth quarter. Union Savings Bank now owns 309 shares of the company’s stock worth $25,000 after acquiring an additional 134 shares during the last quarter. Garner Asset Management Corp purchased a new stake in shares of Colgate-Palmolive during the fourth quarter valued at $30,000. Avion Wealth boosted its position in shares of Colgate-Palmolive by 78.1% during the fourth quarter. Avion Wealth now owns 399 shares of the company’s stock valued at $32,000 after buying an additional 175 shares during the last quarter. Finally, Atlantic Edge Private Wealth Management LLC bought a new position in Colgate-Palmolive in the fourth quarter valued at about $32,000. Institutional investors own 80.41% of the company’s stock.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.